6 studies found for:    22508812 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Docetaxel (AC-Doc) Versus Dose-Dense Doxorubicin and Docetaxel (ADoc) in Breast Cancer
Condition: Primary Breast Cancer
Interventions: Drug: Adriamycin (Doxorubicin), Docetaxel, Tamoxifen;   Drug: Adriamycin (Doxorubicin), Docetaxel, Tamoxifen, Cyclophosphamid
2 Completed Combination Chemotherapy With or Without Capecitabine and/or Trastuzumab Before Surgery in Treating Women With Stage I, Stage II, or Stage III Breast Cancer
Condition: Breast Cancer
Interventions: Biological: trastuzumab;   Drug: capecitabine;   Drug: cyclophosphamide;   Drug: docetaxel;   Drug: epirubicin hydrochloride;   Procedure: adjuvant therapy;   Procedure: conventional surgery;   Procedure: neoadjuvant therapy
3 Unknown  Docetaxel, Doxorubicin and Cyclophosphamide Versus Vinorelbine and Capecitabine in Patients Not Sufficiently / Sufficiently Responding as Preoperative Treatment of Locally Advanced or Operable Primary Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Capecitabine;   Drug: Cyclophosphamide;   Drug: Docetaxel;   Drug: Doxorubicin;   Drug: Vinorelbine
4 Completed Preoperative Epirubicin Paclitaxel Aranesp Study (PREPARE)
Condition: Breast Cancer
Interventions: Drug: Epirubicin, paclitaxel, cyclophosphamide, Methotrexate, 5 FU, darbepoetin alfa;   Drug: Epirubicin, Cyclophosphamide, Paclitaxel, dabepoetin alfa
5 Completed Taxol Epirubicin Cyclophosphamide Herceptin Neoadjuvant (TECHNO)
Condition: Breast Cancer
Intervention: Drug: Epirubicin / Cyclophosphamide in combination with Paclitaxel/Trastuzumab, followed by postoperative Trastuzumab
6 Recruiting A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery
Conditions: Luminal A Breast Cancer;   Luminal B Breast Cancer;   CPS-EG Score;   Postneoadjuvant Treatment With CDK 4/6 Inhibitor;   Hormonreceptor Positive
Interventions: Drug: Palbociclib PD-0332991;   Behavioral: Patient reported outcomes;   Drug: Placebo

Indicates status has not been verified in more than two years